Compare Stocks: IMAB, BCAX, AAPG, and ALVO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$15.93 +5.8%	$17.77	$15.02 ▼ $40.47	$1.49B	0.08	6,797 shs	9,532 shs
ALVO Alvotech	$5.83 -0.8%	$4.28	$2.94 ▼ $9.25	$1.76B	0.22	722,564 shs	968,399 shs
BCAX Bicara Therapeutics	$22.23 -1.8%	$25.21	$10.30 ▼ $30.99	$1.47B	-0.82	595,405 shs	135,996 shs
IMAB I-Mab	$4.76 +2.5%	$4.76	$0.81 ▼ $6.79	$388.29M	1.45	1.61 million shs	1.51 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	0.00%	-6.46%	-11.41%	-12.08%	-61.24%
ALVO Alvotech	0.00%	+10.96%	+32.51%	+60.82%	-25.51%
BCAX Bicara Therapeutics	0.00%	-0.75%	-5.27%	-7.78%	+116.86%
IMAB I-Mab	0.00%	0.00%	0.00%	0.00%	+25.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$15.93 +5.8%	$17.77	$15.02 ▼ $40.47	$1.49B	0.08	6,797 shs	9,532 shs
ALVO Alvotech	$5.83 -0.8%	$4.28	$2.94 ▼ $9.25	$1.76B	0.22	722,564 shs	968,399 shs
BCAX Bicara Therapeutics	$22.23 -1.8%	$25.21	$10.30 ▼ $30.99	$1.47B	-0.82	595,405 shs	135,996 shs
IMAB I-Mab	$4.76 +2.5%	$4.76	$0.81 ▼ $6.79	$388.29M	1.45	1.61 million shs	1.51 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	0.00%	-6.46%	-11.41%	-12.08%	-61.24%
ALVO Alvotech	0.00%	+10.96%	+32.51%	+60.82%	-25.51%
BCAX Bicara Therapeutics	0.00%	-0.75%	-5.27%	-7.78%	+116.86%
IMAB I-Mab	0.00%	0.00%	0.00%	0.00%	+25.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.20	Buy	$46.43	208.29% Upside
ALVO Alvotech	2.50	Moderate Buy	$8.50	44.80% Upside
BCAX Bicara Therapeutics	2.80	Moderate Buy	$32.64	44.15% Upside
IMAB I-Mab	2.83	Moderate Buy	$7.75	62.99% Upside

Current Analyst Ratings Breakdown

Latest IMAB, BCAX, AAPG, and ALVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	ALVO Alvotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	ALVO Alvotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$8.00
9/16/2026	ALVO Alvotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underweight ➝ Overweight	$4.00 ➝ $8.00
9/10/2026	BCAX Bicara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/31/2026	ALVO Alvotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	ALVO Alvotech	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/21/2026	BCAX Bicara Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/21/2026	AAPG Ascentage Pharma Group International	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$35.00
8/18/2026	BCAX Bicara Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	ALVO Alvotech	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$642.64M	2.19	N/A	N/A	$2.04 per share	7.38
ALVO Alvotech	$588.90M	3.01	$0.22 per share	26.94	($0.94) per share	-6.24
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.33 per share	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	$2.47 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$177.71M	N/A	N/A	753.00	N/A	N/A	N/A	N/A	N/A
ALVO Alvotech	$27.92M	-$0.61	N/A	24.46	N/A	-36.31%	-11.92%	-11.73%	11/11/2026 (Estimated)
BCAX Bicara Therapeutics	-$137.95M	-$3.10	N/A	N/A	N/A	N/A	-41.49%	-38.59%	11/9/2026 (Estimated)
IMAB I-Mab	-$22.23M	-$0.36	N/A	N/A	N/A	N/A	-19.65%	-18.58%	N/A

Latest IMAB, BCAX, AAPG, and ALVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	ALVO Alvotech	-$0.0526	-$0.11	-$0.0574	-$0.22	$103.00 million	$106.00 million
8/19/2026	H1 2026	AAPG Ascentage Pharma Group International	N/A	-$0.65	N/A	-$0.6450	N/A	$22.24 million
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	1.09	1.22	1.18
ALVO Alvotech	N/A	1.65	0.96
BCAX Bicara Therapeutics	N/A	11.59	11.59
IMAB I-Mab	N/A	22.82	22.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
ALVO Alvotech	N/A
BCAX Bicara Therapeutics	N/A
IMAB I-Mab	38.38%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
ALVO Alvotech	N/A
BCAX Bicara Therapeutics	13.80%
IMAB I-Mab	22.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	767	93.40 million	N/A	N/A
ALVO Alvotech	1,460	301.81 million	N/A	Not Optionable
BCAX Bicara Therapeutics	103	66.17 million	57.04 million	N/A
IMAB I-Mab	380	81.66 million	63.61 million	Optionable

IMAB, BCAX, AAPG, and ALVO Headlines

Recent News About These Companies

I-Mab stock trades quietly as investors await fresh clinical and earnings catalysts

September 18 at 6:52 PM | ad-hoc-news.deA

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a ...

October 29, 2025 | markets.businessinsider.com

I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

October 29, 2025 | globenewswire.com

I-Mab - Depositary Receipt (IMAB) Price Target Increased by 19.05% to 8.50

October 29, 2025 | msn.com

BTIG Reiterates I-Mab - Depositary Receipt (IMAB) Buy Recommendation

October 24, 2025 | msn.com

I-MAB Reports Positive Phase I Results for Givastomig in Gastroesophageal Cancer

October 24, 2025 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

October 23, 2025 | prnewswire.com

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

October 22, 2025 | globenewswire.com

I-Mab to rebrand as NovaBridge and target Hong Kong dual listing

October 17, 2025 | thepharmaletter.comT

I-Mab tumbles after announcing new business model

October 17, 2025 | msn.com

I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript

October 17, 2025 | seekingalpha.com

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

October 16, 2025 | globenewswire.com

I-Mab Biopharma Stock: Caution Warranted After Huge Surge

October 14, 2025 | seekingalpha.com

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

October 14, 2025 | globenewswire.com

I-Mab's (NASDAQ:IMAB) market cap surged US$52m last week, individual investors who have a lot riding on the company were rewarded

October 11, 2025 | uk.finance.yahoo.com

I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know

October 10, 2025 | zacks.com

What Makes IMab (IMAB) a New Buy Stock

October 6, 2025 | zacks.com

Leerink Partners Initiates Coverage of I-Mab - Depositary Receipt (IMAB) with Outperform Recommendation

October 4, 2025 | msn.com

I-Mab initiated with an Outperform at Leerink

October 3, 2025 | msn.com

I-Mab to Vote on Name Change to NovaBridge Biosciences

September 25, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMAB, BCAX, AAPG, and ALVO Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$15.93 +0.87 (+5.78%)

As of 02:04 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Alvotech NASDAQ:ALVO

$5.82 -0.05 (-0.77%)

As of 02:12 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Bicara Therapeutics NASDAQ:BCAX

$22.23 -0.41 (-1.81%)

As of 02:11 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

I-Mab NASDAQ:IMAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMAB, BCAX, AAPG, and ALVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMAB, BCAX, AAPG, and ALVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMAB, BCAX, AAPG, and ALVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMAB, BCAX, AAPG, and ALVO Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Alvotech NASDAQ:ALVO

Bicara Therapeutics NASDAQ:BCAX

I-Mab NASDAQ:IMAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMAB, BCAX, AAPG, and ALVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMAB, BCAX, AAPG, and ALVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMAB, BCAX, AAPG, and ALVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMAB, BCAX, AAPG, and ALVO Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Alvotech NASDAQ:ALVO

Bicara Therapeutics NASDAQ:BCAX

I-Mab NASDAQ:IMAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools